Hemantane

Last updated

Hemantane
Hemantane.svg
Clinical data
Other namesHymantane; Gimantan; N-Adamant-2-ylhexamethyleneimine; N-(2-Adamantyl)hexamethyleneimine
Identifiers
  • 1-(2-adamantyl)azepane
PubChem CID
ChemSpider
Chemical and physical data
Formula C16H27N
Molar mass 233.399 g·mol−1
3D model (JSmol)
  • C1CCCN(CC1)C2C3CC4CC(C3)CC2C4
  • InChI=1S/C16H27N/c1-2-4-6-17(5-3-1)16-14-8-12-7-13(10-14)11-15(16)9-12/h12-16H,1-11H2
  • Key:JAROVUWOMYMQCW-UHFFFAOYSA-N

Hemantane, or hymantane, also known as N-(2-adamantyl)hexamethyleneimine, is an experimental antiparkinsonian agent of the adamantane family that was never marketed. [1] It was developed and studied in Russia. [1]

It has been said to act as a low-affinity non-competitive NMDA receptor antagonist, as a selective MAO-B inhibitor, and as showing various other actions and effects such as modulation of the dopaminergic and serotonergic systems in the striatum. [1] [2] The drug has also been theorized to be a sigma receptor agonist, which is said to likely be involved in its dopaminergic effects. [1] Analogues of hemantane, such as memantine and amantadine, share some of these actions, like NMDA receptor antagonism, sigma receptor agonism, and dopaminergic modulation. [1]

The drug was first described by 2000. [3] [4]

The dosage of gimantan is standardized to 50mg tablet strength. [5]

See also

Related Research Articles

<span class="mw-page-title-main">Substantia nigra</span> Structure in the basal ganglia of the brain

The substantia nigra (SN) is a basal ganglia structure located in the midbrain that plays an important role in reward and movement. Substantia nigra is Latin for "black substance", reflecting the fact that parts of the substantia nigra appear darker than neighboring areas due to high levels of neuromelanin in dopaminergic neurons. Parkinson's disease is characterized by the loss of dopaminergic neurons in the substantia nigra pars compacta.

<span class="mw-page-title-main">NMDA receptor</span> Glutamate receptor and ion channel protein found in nerve cells

The N-methyl-D-aspartatereceptor (also known as the NMDA receptor or NMDAR), is a glutamate receptor and predominantly Ca2+ ion channel found in neurons. The NMDA receptor is one of three types of ionotropic glutamate receptors, the other two being AMPA and kainate receptors. Depending on its subunit composition, its ligands are glutamate and glycine (or D-serine). However, the binding of the ligands is typically not sufficient to open the channel as it may be blocked by Mg2+ ions which are only removed when the neuron is sufficiently depolarized. Thus, the channel acts as a "coincidence detector" and only once both of these conditions are met, the channel opens and it allows positively charged ions (cations) to flow through the cell membrane. The NMDA receptor is thought to be very important for controlling synaptic plasticity and mediating learning and memory functions.

<span class="mw-page-title-main">Amantadine</span> Medication used to treat dyskinesia

Amantadine, sold under the brand name Gocovri among others, is a medication used to treat dyskinesia associated with parkinsonism and influenza caused by type A influenzavirus, though its use for the latter is no longer recommended because of widespread drug resistance. It is also used for a variety of other uses. The drug is taken by mouth.

<span class="mw-page-title-main">Phenylpiracetam</span> Chemical compound

Phenylpiracetam, also known as fonturacetam and sold under the brand names Phenotropil, Actitropil, and Carphedon among others, is a stimulant and nootropic medication used in Russia and certain other Eastern European countries in the treatment of cerebrovascular deficiency, depression, apathy, and attention, and memory problems, among other indications. It is also used in Russian cosmonauts to improve physical, mental, and cognitive abilities. The drug is taken by mouth.

<span class="mw-page-title-main">Dopaminergic</span> Substance related to dopamine functions

Dopaminergic means "related to dopamine", a common neurotransmitter. Dopaminergic substances or actions increase dopamine-related activity in the brain.

<span class="mw-page-title-main">Gidazepam</span> Benzodiazepine medication

Gidazepam, also known as hydazepam or hidazepam, is a drug which is an atypical benzodiazepine derivative, developed in the Soviet Union. It is a selectively anxiolytic benzodiazepine. It also has therapeutic value in the management of certain cardiovascular disorders.

<span class="mw-page-title-main">Mesocarb</span> Stimulant drug

Mesocarb, sold under the brand name Sidnocarb or Sydnocarb and known by the developmental code name MLR-1017, is a psychostimulant medication which has been used in the treatment of psychiatric disorders and for a number of other indications in the Soviet Union and Russia. It is currently under development for the treatment of Parkinson's disease and sleep disorders. It is taken by mouth.

<span class="mw-page-title-main">Latrepirdine</span> Antihistamine drug

Latrepirdine is an antihistamine drug which has been used clinically in Russia since 1983.

<span class="mw-page-title-main">Budipine</span> Pharmaceutical drug

Budipine is an antiparkinson agent marketed for the treatment of Parkinson's disease.

<span class="mw-page-title-main">Feprosidnine</span> Chemical compound

Feprosidnine, sold under the brand name Sydnophen, is a stimulant drug which was developed in the USSR in the 1970s. It is structurally related to another Russian drug mesocarb but unlike mesocarb, was withdrawn earlier from production. In comparison with mesocarb it has own antidepressant activity, which makes it useful in treating depressions. Indications of feprosidnine included apathic, asthenic depressions, fatigue, apathic syndrome, narcolepsy and other similar conditions. Therapeutic range of doses: 10-50mg a day. Sydnophen has multiple mechanisms of action, the relative importance of which has not been clearly established. Effects on the body include reversible monoamine oxidase inhibition, cholinergic, adrenergic, opioid and nitric oxide donating actions, all of which may contribute to its pharmacological effects to some extent.

<span class="mw-page-title-main">Bromantane</span> Stimulant drug

Bromantane, sold under the brand name Ladasten, is an atypical central nervous system (CNS) stimulant and anxiolytic drug of the adamantane family that is related to amantadine and memantine. Medically, it is approved in Russia for the treatment of neurasthenia. Although the effects of bromantane have been determined to be dependent on the dopaminergic and possibly serotonergic neurotransmitter systems, its exact mechanism of action is unknown, and is distinct in its properties relative to typical stimulants such as amphetamine. Bromantane has sometimes been described as an actoprotector.

<i>N</i>-Phenylacetyl-<small>L</small>-prolylglycine ethyl ester Prodrug

N-Phenylacetyl-l-prolylglycine ethyl ester is promoted as a nootropic and is a prodrug of cyclic glycine-proline. Other names include the brand name Noopept, developmental code GVS-111, and proposed INN omberacetam.

<span class="mw-page-title-main">Fabomotizole</span> Anxiolytic drug

Fabomotizole is an anxiolytic drug launched in Russia in the early 2000s. It produces anxiolytic and neuroprotective effects without any sedative or muscle relaxant actions. Its mechanism of action remains poorly defined however, with GABAergic, NGF- and BDNF-release-promoting, MT1 receptor agonism, MT3 receptor antagonism, and sigma agonism suggested as potential mechanisms. Fabomotizole was shown to inhibit MAO-A reversibly and there might be also some involvement with serotonin receptors. Clinical trials have shown fabomotizole to be well tolerated and reasonably effective for the treatment of anxiety.

<span class="mw-page-title-main">Selank</span> Chemical compound

Selank is a nootropic, anxiolytic peptide based drug developed by the Institute of Molecular Genetics of the Russian Academy of Sciences. Selank is a heptapeptide with the sequence Thr-Lys-Pro-Arg-Pro-Gly-Pro (TKPRPGP). It is a synthetic analogue of human tuftsin.

<span class="mw-page-title-main">Emoxypine</span> Chemical compound

Emoxypine (2-ethyl-6-methyl-3-hydroxypyridine), also known as Mexidol or Mexifin, a succinate salt, is chemical compound which is claimed by its manufacturer, the Russian company Pharmasoft Pharmaceuticals, to have antioxidant and actoprotector properties, but these purported properties of emoxypine have not been proven. Its chemical structure resembles that of pyridoxine (a type of vitamin B6).

<span class="mw-page-title-main">Benzobarbital</span> Chemical compound

Benzobarbital (Benzonal) is a barbiturate derivative. It has anticonvulsant effects and has been used for the treatment of epilepsy.

<span class="mw-page-title-main">Nooglutyl</span> Chemical compound

Nooglutyl is a nootropic agent that was studied at the Research Institute of Pharmacology, Russian Academy of Medical Sciences as a potential treatment for amnesia.

<span class="mw-page-title-main">Semax</span> Chemical compound

Semax is a medication which is used in Russia and Eastern Europe for the treatment of a broad range of conditions like brain trauma but predominantly for its claimed nootropic, neuroprotective, and neurorestorative effects.

<span class="mw-page-title-main">Adapromine</span> Chemical compound

Adapromine is an antiviral drug of the adamantane group related to amantadine (1-aminoadamantane), rimantadine, and memantine (1-amino-3,5-dimethyladamantane) that is marketed in Russia for the treatment and prevention of influenza. It is an alkyl analogue of rimantadine and is similar to rimantadine in its antiviral activity but possesses a broader spectrum of action, being effective against influenza viruses of both type A and B. Strains of type A influenza virus with resistance to adapromine and rimantadine and the related drug deitiforine were encountered in Mongolia and the Soviet Union in the 1980s.

<span class="mw-page-title-main">Mesdopetam</span> Chemical compound

Mesdopetam (INNTooltip International Nonproprietary Name; developmental code names IRL-790, IPN60170) is a dopamine D2 and D3 receptor antagonist with preference for the D3 receptor which is under development for the treatment of Parkinson's disease, drug-induced dyskinesia, and psychotic disorders. It has been described by its developers as having "psychomotor stabilizing" properties.

References

  1. 1 2 3 4 5 Abaimov DA, Kovalev GI (2011). "Sigma receptors as a pharmacological target for neuroprotectors. New horizons of pharmacotherapy of Parkinson disease". Neurochemical Journal. 5 (2): 83–91. doi:10.1134/S1819712411010028. ISSN   1819-7124.
  2. Fischler PV, Soyka M, Seifritz E, Mutschler J (2022). "Off-label and investigational drugs in the treatment of alcohol use disorder: A critical review". Frontiers in Pharmacology. 13: 927703. doi: 10.3389/fphar.2022.927703 . PMC   9574013 . PMID   36263121.
  3. Val'dman EA (2000). "[Pharmacological activity of the new adamantane derivative--potential antiparkinson preparation during subchronic administration]". Eksperimental'naia i Klinicheskaia Farmakologiia (in Russian). 63 (5): 3–6. PMID   11109514.
  4. Andiarzhanova EA, Val'dman EA, Kudrin VS, Raevskiĭ KS, Voronina TA (2001). "[Effect of the new potential anti-Parkinson agent, hymantane, on levels of monoamines and their metabolites in rat striatum (a microdialysis study)]". Eksperimental'naia i Klinicheskaia Farmakologiia (in Russian). 64 (6): 13–16. PMID   11871228.
  5. Tsvetkova EA, Volkova MY, Stepanenko OB, Kislyak NA, Shcherbakova OV, Avdyunina NI, et al. (January 2002). "Gimantan Tablets: Analysis and Standardization". Pharmaceutical Chemistry Journal. 36 (1): 48–50. doi:10.1023/A:1015761110991.